DE60234248D1 - Pharmazeutika und verfahren zur hypoxiebehandlung und screening-verfahren dafür - Google Patents

Pharmazeutika und verfahren zur hypoxiebehandlung und screening-verfahren dafür

Info

Publication number
DE60234248D1
DE60234248D1 DE60234248T DE60234248T DE60234248D1 DE 60234248 D1 DE60234248 D1 DE 60234248D1 DE 60234248 T DE60234248 T DE 60234248T DE 60234248 T DE60234248 T DE 60234248T DE 60234248 D1 DE60234248 D1 DE 60234248D1
Authority
DE
Germany
Prior art keywords
treatment
hypoxy
pharmaceuticals
therefor
screening
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60234248T
Other languages
English (en)
Inventor
William G Kaelin
Mircea Ivan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27580991&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60234248(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Application granted granted Critical
Publication of DE60234248D1 publication Critical patent/DE60234248D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/11—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with 2-oxoglutarate as one donor, and incorporation of one atom each of oxygen into both donors (1.14.11)
    • C12Y114/11002—Procollagen-proline dioxygenase (1.14.11.2), i.e. proline-hydroxylase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90245—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
DE60234248T 2001-03-20 2002-03-20 Pharmazeutika und verfahren zur hypoxiebehandlung und screening-verfahren dafür Expired - Lifetime DE60234248D1 (de)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US27742501P 2001-03-20 2001-03-20
US27743101P 2001-03-20 2001-03-20
US27744001P 2001-03-20 2001-03-20
US33233401P 2001-11-09 2001-11-09
US33249301P 2001-11-09 2001-11-09
US34520001P 2001-11-09 2001-11-09
US34259801P 2001-12-20 2001-12-20
US34513201P 2001-12-20 2001-12-20
US34513101P 2001-12-20 2001-12-20
US10/101,812 US6855510B2 (en) 2001-03-20 2002-03-19 Pharmaceuticals and methods for treating hypoxia and screening methods therefor
PCT/US2002/008886 WO2002074249A2 (en) 2001-03-20 2002-03-20 Pharmaceuticals and methods for treating hypoxia and screening methods therefor

Publications (1)

Publication Number Publication Date
DE60234248D1 true DE60234248D1 (de) 2009-12-17

Family

ID=27580991

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60234248T Expired - Lifetime DE60234248D1 (de) 2001-03-20 2002-03-20 Pharmazeutika und verfahren zur hypoxiebehandlung und screening-verfahren dafür

Country Status (9)

Country Link
US (10) US6855510B2 (de)
EP (3) EP2343062A1 (de)
JP (4) JP4116442B2 (de)
AT (1) ATE447620T1 (de)
AU (1) AU2002252466A1 (de)
CA (1) CA2441291C (de)
DE (1) DE60234248D1 (de)
ES (1) ES2335751T3 (de)
WO (1) WO2002074249A2 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6123715A (en) * 1994-07-08 2000-09-26 Amplatz; Curtis Method of forming medical devices; intravascular occlusion devices
US6673554B1 (en) * 1999-06-14 2004-01-06 Trellie Bioinformatics, Inc. Protein localization assays for toxicity and antidotes thereto
US7919274B2 (en) * 2001-03-20 2011-04-05 Dana-Farber Cancer Institute, Inc. Light-emitting fusion proteins and diagnostic and therapeutic methods therefor
US6855510B2 (en) * 2001-03-20 2005-02-15 Dana Farber Cancer Institute, Inc. Pharmaceuticals and methods for treating hypoxia and screening methods therefor
WO2002074981A2 (en) 2001-03-21 2002-09-26 Isis Innovation Ltd. Assays, methods and means relating to hypoxia inducible factor (hif) hydroxylase
CN102526044A (zh) 2001-12-06 2012-07-04 法布罗根股份有限公司 提高内源性红细胞生成素(epo)的方法
WO2003074560A2 (en) * 2002-03-05 2003-09-12 Angiogenetics Sweden Ab Critical hypoxia-inducible factor-1alpha residues, products and methods related thereto
JP4097485B2 (ja) * 2002-08-28 2008-06-11 独立行政法人科学技術振興機構 酸化還元酵素と基質との反応中間体を捕捉する方法
US8124582B2 (en) * 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
US20060251638A1 (en) * 2003-06-06 2006-11-09 Volkmar Guenzler-Pukall Cytoprotection through the use of hif hydroxylase inhibitors
US7323475B2 (en) * 2003-06-06 2008-01-29 Fibrogen, Inc. Nitrogen-containing heteroaryl compounds and methods of use thereof
US20050214894A1 (en) * 2004-03-26 2005-09-29 Schofield Christopher J High throughput assay
WO2006084210A2 (en) * 2005-02-04 2006-08-10 Regents Of The University Of California, San Diego Hif modulating compounds and methods of use thereof
CA2611785A1 (en) * 2005-06-15 2006-12-28 Fibrogen, Inc. Use of hif 1alfa modulators for treatment of cancer
EP1991269A1 (de) 2006-02-16 2008-11-19 Fibrogen, Inc. Verbindungen und verfahren zur behandlung von apoplexie
US7588924B2 (en) 2006-03-07 2009-09-15 Procter & Gamble Company Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
CA2659682C (en) 2006-06-26 2010-12-21 The Procter & Gamble Company Prolyl hydroxylase inhibitors and methods of use
JP2010085108A (ja) * 2008-09-29 2010-04-15 Nano Factory:Kk 生体光イメージング用プローブ
TW201029676A (en) * 2009-02-05 2010-08-16 Yuk Kwan Liu Formulation for the treatment of hypoxia and related disorders
KR20140122283A (ko) * 2009-11-06 2014-10-17 에르피오 세러퓨틱스 인코포레이티드 저산소증 유발 인자-1 알파의 안정화 증가 방법
NO2686520T3 (de) 2011-06-06 2018-03-17
WO2013075065A1 (en) * 2011-11-18 2013-05-23 Memorial Sloan-Kettering Cancer Center 2-hydroxyglutarate as a biomarker for chronic hypoxia
CN103435546B (zh) 2012-07-16 2016-08-10 菲布罗根有限公司 制备异喹啉化合物的方法
KR20220164068A (ko) 2012-07-16 2022-12-12 피브로겐, 인크. 프롤릴 하이드록실라제 억제제 [(4-하이드록시-1-메틸-7-페녹시-아이소퀴놀린-3-카보닐)-아미노]-아세트산의 결정형
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
JP6406759B6 (ja) * 2013-03-27 2018-12-05 国立大学法人九州大学 ナノカプセル、組成物、ポリヌクレオチド、組換えベクター及び形質転換体
JP5661148B2 (ja) * 2013-06-10 2015-01-28 オリエンタル酵母工業株式会社 生体光イメージング用プローブ
SG10201910773VA (en) 2013-06-13 2020-01-30 Akebia Therapeutics Inc Compositions and methods for treating anemia
CA2930128A1 (en) 2013-11-15 2015-05-21 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
CA2934662C (en) * 2013-12-20 2024-02-20 President And Fellows Of Harvard College Low shear microfluidic devices and methods of use and manufacturing thereof
WO2015148950A1 (en) 2014-03-28 2015-10-01 Memorial Sloan-Kettering Cancer Center L-2-hydroxyglutarate and stress induced metabolism
CN107427503A (zh) 2015-01-23 2017-12-01 阿克比治疗有限公司 2‑(5‑(3‑氟苯基)‑3‑羟基吡啶甲酰胺)乙酸的固体形式、其组合物及用途
IL305910A (en) 2015-04-01 2023-11-01 Akebia Therapeutics Inc Formulation of an oral administration form of }]5-)3-chlorophenyl(-3-hydroxypyridine-2-carbonyl[amino{acetic acid
US10543724B2 (en) * 2015-05-05 2020-01-28 Jhonatan SHEMESH Wheel rim accessory and method for assembling thereof
AU2018337686B2 (en) * 2017-09-21 2023-04-20 Merck Patent Gmbh Fusion protein comprising an FGF-18 moiety
US11713298B2 (en) 2018-05-09 2023-08-01 Akebia Therapeutics, Inc. Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4540564A (en) 1982-05-18 1985-09-10 University Of Florida Brain-specific drug delivery
US5087618A (en) 1982-05-18 1992-02-11 University Of Florida Redox carriers for brain-specific drug delivery
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
WO1987003304A1 (en) * 1985-12-02 1987-06-04 The Regents Of The University Of California Isolation of dna sequences encoding luciferase activity and applications of the same
US5166320A (en) 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
US5021404A (en) * 1988-04-20 1991-06-04 The Children's Medical Center Corporation Angiostatic collagen modulators
DE3818850A1 (de) * 1988-06-03 1989-12-07 Hoechst Ag Oligopeptide mit zyklischen prolin-analogen aminosaeuren
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5683888A (en) 1989-07-22 1997-11-04 University Of Wales College Of Medicine Modified bioluminescent proteins and their use
US5233409A (en) 1992-02-25 1993-08-03 Schwab Karl W Color analysis of organic constituents in sedimentary rocks for thermal maturity
US6649143B1 (en) * 1994-07-01 2003-11-18 The Board Of Trustees Of The Leland Stanford Junior University Non-invasive localization of a light-emitting conjugate in a mammal
US5650135A (en) 1994-07-01 1997-07-22 The Board Of Trustees Of The Leland Stanford Junior University Non-invasive localization of a light-emitting conjugate in a mammal
US6046219A (en) * 1995-01-20 2000-04-04 Cornell Research Foundation, Inc. Method for the treatment of conditions mediated by collagen formation together with cell proliferation by application of inhibitors of protein hydroxylation
US5958713A (en) 1995-01-31 1999-09-28 Novo Nordisk A/S Method of detecting biologically active substances by using green fluorescent protein
US5882914A (en) * 1995-06-06 1999-03-16 The Johns Hopkins University School Of Medicine Nucleic acids encoding the hypoxia inducible factor-1
GB9911047D0 (en) * 1999-05-12 1999-07-14 Isis Innovation Assay method and means
US6849718B2 (en) * 2001-03-20 2005-02-01 Dana Farber Cancer Institute, Inc. Muteins of hypoxia inducible factor alpha and methods of use thereof
US7176345B2 (en) * 2001-03-20 2007-02-13 Dana-Farber Cancer Institute, Inc. Transgenic animals expressing light-emitting fusion proteins and diagnostic and therapeutic methods therefor
US6855510B2 (en) 2001-03-20 2005-02-15 Dana Farber Cancer Institute, Inc. Pharmaceuticals and methods for treating hypoxia and screening methods therefor
US7919274B2 (en) * 2001-03-20 2011-04-05 Dana-Farber Cancer Institute, Inc. Light-emitting fusion proteins and diagnostic and therapeutic methods therefor
WO2002074981A2 (en) * 2001-03-21 2002-09-26 Isis Innovation Ltd. Assays, methods and means relating to hypoxia inducible factor (hif) hydroxylase
US6566088B1 (en) * 2001-10-04 2003-05-20 Board Of Regents, The University Of Texas System Prolyl-4-hydroxylases
CN102526044A (zh) * 2001-12-06 2012-07-04 法布罗根股份有限公司 提高内源性红细胞生成素(epo)的方法
US7053046B2 (en) * 2001-12-21 2006-05-30 Mcgrath Kevin Peptide activators of VEGF
US20050214894A1 (en) * 2004-03-26 2005-09-29 Schofield Christopher J High throughput assay
US20060003961A1 (en) * 2004-06-18 2006-01-05 The John Hopkins University Negative regulation of hypoxia inducible factor 1 by OS-9
CN101394843A (zh) * 2005-06-06 2009-03-25 菲布罗根公司 使用HIFα稳定剂的改进的贫血治疗
KR100859506B1 (ko) * 2005-07-22 2008-09-22 한국과학기술연구원 프롤린 수산화반응에 의한 ｈｉｆ―1 펩타이드와 ｖｂｃ단백질과의 상호작용을 형광편광도를 이용하여 정량적으로분석하는 방법
US7728130B2 (en) * 2005-12-09 2010-06-01 Amgen Inc. Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity
WO2008040002A2 (en) * 2006-09-28 2008-04-03 Fred Hutchinson Cancer Research Center Methods, compositions and articles of manufacture for hif modulating compounds
US20100240069A1 (en) * 2009-03-18 2010-09-23 Boehringer Ingelheim International Gmbh Drug Discovery Assay for Modulators of HIF-Prolyl Hydroxylase Activity

Also Published As

Publication number Publication date
JP4344770B2 (ja) 2009-10-14
US20220291216A1 (en) 2022-09-15
US20200209239A1 (en) 2020-07-02
US20130115221A1 (en) 2013-05-09
JP4116442B2 (ja) 2008-07-09
US10365278B2 (en) 2019-07-30
US9766240B2 (en) 2017-09-19
US20170350891A1 (en) 2017-12-07
EP1377676B1 (de) 2009-11-04
US20020192737A1 (en) 2002-12-19
US20150010576A1 (en) 2015-01-08
US7985563B2 (en) 2011-07-26
US20090029400A1 (en) 2009-01-29
WO2002074249A2 (en) 2002-09-26
WO2002074249A3 (en) 2003-03-06
JP2009040785A (ja) 2009-02-26
US6855510B2 (en) 2005-02-15
JP2011006477A (ja) 2011-01-13
US8809011B2 (en) 2014-08-19
US20040248233A1 (en) 2004-12-09
AU2002252466A1 (en) 2002-10-03
EP2179730A1 (de) 2010-04-28
EP1377676A4 (de) 2005-11-02
ATE447620T1 (de) 2009-11-15
JP2004533224A (ja) 2004-11-04
EP1377676A2 (de) 2004-01-07
US20050186650A1 (en) 2005-08-25
EP2343062A1 (de) 2011-07-13
CA2441291C (en) 2016-06-14
ES2335751T3 (es) 2010-04-05
US20100233735A1 (en) 2010-09-16
CA2441291A1 (en) 2002-09-26
JP2008150382A (ja) 2008-07-03

Similar Documents

Publication Publication Date Title
DE60234248D1 (de) Pharmazeutika und verfahren zur hypoxiebehandlung und screening-verfahren dafür
DE69728594D1 (de) Chromfreie Zusammensetzung zur Behandlung von Metalloberflächen
DE69910368D1 (de) Pyrazolopyrimidinone cgmp pde5 inhibitoren zur behandlung von sexualfunktionsstörungen
DE69837783D1 (de) Verfahren und Gerät zur Bereitstellung von Anrufdienste über Internet
DE69714630T2 (de) Biosensor und Verfahren zur quantitaven Analyse von biochemischen Substraten
DK1787980T3 (da) Krystallint og rent modafinil og fremgangsmåde til atfremstille dette
IS2715B (is) Ný notkun fyrir búdesóníð og formóteról
DE69526684D1 (de) Begasungsrührwerk zur Behandlung von Metallschmelzen
DK0918774T3 (da) Androgenreceptormodulatorforbindelser og fremgangsmåder
DE60226797D1 (de) Instrument zum Einbringen von Befestigungselementen für Transplantate
DE60232754D1 (de) Vorrichtung und Verfahren zur Informationsaufzeichnung
DE69942588D1 (de) Verfahren zur reduktion von emittiertem kohlendioxid
ATE520466T1 (de) Apparat und verfahren zur modifizierung von magnetisch inmmobilizierte biomolekulen
DE69926477D1 (de) Verfahren und Vorrichtung zur dynamischen Steuerung der Bereitstellung von differenzierter Diensten
DE60206393T2 (de) Verfahren zur verwaltung des kaufs von rundsende-digitalinhalten und mittel zum herunterladen dieser
DE60103511D1 (de) Verfahren und vorrichtung zur gleichzeitigen aufnahme und wiedergabe von zwei verschiedenen videoprogrammen
DE69911654D1 (de) Verfahren zur verringerung des metallgehalts von erdölströmen
DE60043207D1 (de) Verfahren und Vorrichtung zur Reinigung von Gasen
DE60201278D1 (de) Verfahren und Vorrichtung zur Wendung und Ausgabe von Bögen und diese verwendendes Bilderzeugungsgerät
ATE428425T1 (de) Spla2-inhibitoren zur behandlung von arteriosklerose
PT710109E (pt) Metodo para identificar um inibidor de pde iv
DE50212310D1 (de) Verfahren und Einrichtung für den Transfer von Werkstücken
DE60005317D1 (de) Verfahren zur oxidation von cycloalkanen, cycloalkoholen und/oder cycloketonen
DE69811533D1 (de) Verfahren zur vermehrung der produktion und zur verbesserung der qualität von sperma
DE69419191T2 (de) Verfahren zur Erhöhung des Oxydationswiderstandes von einen Fe-Cr-Al Legierung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition